You are here: Industry Insights > Lilly

News List

Lilly Announces Agreement to Acquire ARMO BioSciences americanpharmaceuticalreview
May 18, 2018
Eli Lilly and Company and ARMO BioSciences announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion,
Lilly's Galcanezumab Meets Primary Endpoint americanpharmaceuticalreview
May 18, 2018
Eli Lilly and Company announced galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache,
Lilly to acquire AurKa Pharma biospectrumasia
May 16, 2018
Acquisition Expands Lilly Oncology Pipeline with Early-Phase Asset Being Studied in Multiple Tumor Types
Lilly boosts immuno-oncology pipeline with $1.6B Armo buy fiercebiotech
May 16, 2018
Eli Lilly is ponying up about $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin, which has shown promise both as a single agent and in combination treatments for multiple tumor types.
Lilly buys ARMO BioSciences for $1.6 billion pharmatimes
May 15, 2018
Eli Lilly is buying ARMO BioSciences in a deal valued at around $1.6 billion, to ramp up its immune-oncology pipeline.
Lilly moves quickly to secure $1.6bn buyout of Armo pharmafile
May 15, 2018
Armo BioSciences only went public in January but it has already been snapped up by Eli Lilly for $1.6 billion.
Lilly Announces Agreement To Acquire ARMO BioSciences pharmafocusasia
May 14, 2018
Eli Lilly and Company and ARMO BioSciences, Inc. announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction.
Lilly and Alder showcase latest migraine drug data pharmaphorum
April 26, 2018
A gang of new migraine drugs are nearing approval, and new data is emerging from contenders from Eli Lilly, and its upstart rival Alder Biopharmaceuticals as they prepare their bids for a highly competitive market.
Lilly's arthritis drug found to prevent potentially lethal stem cell transplant complications pharmafile
April 26, 2018
Researchers at St Louis Washington University School of Medicine have uncovered a promising extra application of a particular Janus Kinase (JAK) inhibitor
Lilly and Incyte's resubmission of arthritis drug data fails to assuage FDA concerns pharmafile
April 23, 2018
Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib after the FDA raised concerns over its safety in a resubmission of data following rejection last year.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page